Does PEMBROLIZUMAB Cause Bladder transitional cell carcinoma? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Bladder transitional cell carcinoma have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.
8
Reports of Bladder transitional cell carcinoma with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
2
Deaths
3
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From PEMBROLIZUMAB?
Of the 8 reports, 2 (25.0%) resulted in death, 3 (37.5%) required hospitalization, and 1 (12.5%) were considered life-threatening.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which PEMBROLIZUMAB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G